Supplementary Figures S1-S4 with Legends from Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Supplementary Fig. S1. Therapeutic efficacy of RV and HDACi against cancer B cells; Supplementary Fig. S2. HDACi increase JAM-1 expression without affecting cell viability; Supplementary Fig. S3. RV+HDACi display synergistic anti-myeloma activity; Supplementary Fig. S4. Combination treatment of MCL cells with RV and HDAC inhibitors results in increased cell death, compared to single agent treatments.